中华核医学与分子影像杂志
中華覈醫學與分子影像雜誌
중화핵의학여분자영상잡지
Chinese Journal of Nuclear Medicine and Molecular Imaging
2015年
5期
387-390
,共4页
刘雪辉%李洪均%于鸿煦%周爽%楼明
劉雪輝%李洪均%于鴻煦%週爽%樓明
류설휘%리홍균%우홍후%주상%루명
辐射剂量%体层摄影术,发射型计算机,单光子%体层摄影术,X线计算机%MDP%MIBI%MAA
輻射劑量%體層攝影術,髮射型計算機,單光子%體層攝影術,X線計算機%MDP%MIBI%MAA
복사제량%체층섭영술,발사형계산궤,단광자%체층섭영술,X선계산궤%MDP%MIBI%MAA
Radiation dosage%Tomography,emission-computed,single-photon%Tomography,X-ray,computed%MDP%MIBI%MAA
目的 评估SPECT/CT同机融合显像所致患者有效剂量.方法 回顾性研究2013年4月至2014年9月157例接受SPECT/CT检查的患者,男85例,女72例,年龄24～ 88(60.46± 13.44)岁;其中99Tcm-MDP骨显像组113例,99Tcm-MIBI甲状旁腺显像组23例,99Tcm-MAA肺血流灌注显像组21例.记录注入患者体内的放射性核素活度(MBq),应用国际辐射防护委员会(ICRP)推荐公式计算放射性核素所致有效剂量.记录同机CT检查时CT容积剂量指数(CTDIvol)以及剂量长度乘积(DLP),并根据有效剂量转换因子(K)估算CT检查所致有效剂量.对不同显像组间检查所致有效剂量进行分析,多组间均数比较采用Kruskal-Wallis秩和检验,2组均数比较采用Wilcoxon秩和检验.结果 99Tcm-MDP骨显像组放射性核素所致有效剂量为(4.02±0.35) mSv、99Tcm-MIBI甲状旁腺显像组为(6.13±0.53) mSy、99Tcm-MAA肺血流灌注显像组为(1.66±0.13) mSv,差异有统计学意义(x2=96.853,P＜0.05),两两比较差异均有统计学意义(Z=7.533、7.262和5.676,均P＜0.05);同机CT检查所致有效剂量分别为(3.84± 1.98)、(1.04±0.19)和(4.05±0.47) mSy,差异有统计学意义(x2=41.225,P＜0.05),甲状旁腺显像组与骨显像组、肺血流灌注显像组差异均有统计学意义(Z=6.046和5.672,均P＜0.05).SPECT/CT检查总有效剂量分别为(7.86± 1.98)、(7.17±0.81)和(5.71±0.45) mSv,差异有统计学意义(x2=28.988,P＜0.05),肺血流灌注显像组与骨显像组、甲状旁腺显像组差异均有统计学意义(Z=4.967和4.994,均P＜0.05).结论 SPECT/CT检查时同机CT扫描可增加患者所受有效剂量,日常使用时应遵循实践正当化及最优化原则.
目的 評估SPECT/CT同機融閤顯像所緻患者有效劑量.方法 迴顧性研究2013年4月至2014年9月157例接受SPECT/CT檢查的患者,男85例,女72例,年齡24～ 88(60.46± 13.44)歲;其中99Tcm-MDP骨顯像組113例,99Tcm-MIBI甲狀徬腺顯像組23例,99Tcm-MAA肺血流灌註顯像組21例.記錄註入患者體內的放射性覈素活度(MBq),應用國際輻射防護委員會(ICRP)推薦公式計算放射性覈素所緻有效劑量.記錄同機CT檢查時CT容積劑量指數(CTDIvol)以及劑量長度乘積(DLP),併根據有效劑量轉換因子(K)估算CT檢查所緻有效劑量.對不同顯像組間檢查所緻有效劑量進行分析,多組間均數比較採用Kruskal-Wallis秩和檢驗,2組均數比較採用Wilcoxon秩和檢驗.結果 99Tcm-MDP骨顯像組放射性覈素所緻有效劑量為(4.02±0.35) mSv、99Tcm-MIBI甲狀徬腺顯像組為(6.13±0.53) mSy、99Tcm-MAA肺血流灌註顯像組為(1.66±0.13) mSv,差異有統計學意義(x2=96.853,P＜0.05),兩兩比較差異均有統計學意義(Z=7.533、7.262和5.676,均P＜0.05);同機CT檢查所緻有效劑量分彆為(3.84± 1.98)、(1.04±0.19)和(4.05±0.47) mSy,差異有統計學意義(x2=41.225,P＜0.05),甲狀徬腺顯像組與骨顯像組、肺血流灌註顯像組差異均有統計學意義(Z=6.046和5.672,均P＜0.05).SPECT/CT檢查總有效劑量分彆為(7.86± 1.98)、(7.17±0.81)和(5.71±0.45) mSv,差異有統計學意義(x2=28.988,P＜0.05),肺血流灌註顯像組與骨顯像組、甲狀徬腺顯像組差異均有統計學意義(Z=4.967和4.994,均P＜0.05).結論 SPECT/CT檢查時同機CT掃描可增加患者所受有效劑量,日常使用時應遵循實踐正噹化及最優化原則.
목적 평고SPECT/CT동궤융합현상소치환자유효제량.방법 회고성연구2013년4월지2014년9월157례접수SPECT/CT검사적환자,남85례,녀72례,년령24～ 88(60.46± 13.44)세;기중99Tcm-MDP골현상조113례,99Tcm-MIBI갑상방선현상조23례,99Tcm-MAA폐혈류관주현상조21례.기록주입환자체내적방사성핵소활도(MBq),응용국제복사방호위원회(ICRP)추천공식계산방사성핵소소치유효제량.기록동궤CT검사시CT용적제량지수(CTDIvol)이급제량장도승적(DLP),병근거유효제량전환인자(K)고산CT검사소치유효제량.대불동현상조간검사소치유효제량진행분석,다조간균수비교채용Kruskal-Wallis질화검험,2조균수비교채용Wilcoxon질화검험.결과 99Tcm-MDP골현상조방사성핵소소치유효제량위(4.02±0.35) mSv、99Tcm-MIBI갑상방선현상조위(6.13±0.53) mSy、99Tcm-MAA폐혈류관주현상조위(1.66±0.13) mSv,차이유통계학의의(x2=96.853,P＜0.05),량량비교차이균유통계학의의(Z=7.533、7.262화5.676,균P＜0.05);동궤CT검사소치유효제량분별위(3.84± 1.98)、(1.04±0.19)화(4.05±0.47) mSy,차이유통계학의의(x2=41.225,P＜0.05),갑상방선현상조여골현상조、폐혈류관주현상조차이균유통계학의의(Z=6.046화5.672,균P＜0.05).SPECT/CT검사총유효제량분별위(7.86± 1.98)、(7.17±0.81)화(5.71±0.45) mSv,차이유통계학의의(x2=28.988,P＜0.05),폐혈류관주현상조여골현상조、갑상방선현상조차이균유통계학의의(Z=4.967화4.994,균P＜0.05).결론 SPECT/CT검사시동궤CT소묘가증가환자소수유효제량,일상사용시응준순실천정당화급최우화원칙.
Objective To assess the patient effective dose during SPECT/CT imaging.Methods A total of 157 patients (85 males,72 females;mean age:(60.46±13.44) years,range:24-88 years) who underwent SPECT/CT from April 2013 to September 2014 were retrospectively analyzed.They were divided into 3 groups:99Tcm-MDP bone scan group (n=113),99Tcm-MIBI parathyroid imaging group (n=23) and 99Tcm-MAA pulmonary perfusion imaging group (n=21).The injection dose (MBq) was recorded and the effective dose (mSv) was estimated according to the International Commission on Radiological Protection (ICRP) guideline.The volume-weighted computed tomography dose index (CTDIvol) and dose length product (DLP) of CT were also recorded and the effective dose (mSv) due to CT was calculated.The effective doses among different groups were statistically compared by Kruskal-Wallis rank sum test and Wilcoxon rank sum test.Results The effective dose from radiopharmaceuticals were (4.02±0.35) mSv for 99Tcm-MDP bone scan,(6.13±0.53) mSv for 99Tcm-MIBI parathyroid imaging and (1.66±0.13) mSv for 99Tcm-MAA pulmonary perfusion imaging (x2=96.853;Z =7.533,7.262 and 5.676;all P＜ 0.05).The effective dose due to CT were (3.84±1.98),(1.04±0.19),(4.05±0.47) mSv respectively (x2 =41.225,P＜0.05),and there were significant differences between 99Tcm-MIBI parathyroid imaging group and 99Tcm-MDP bone scan group,99Tcm-MAA pulmonary perfusion imaging group(Z=6.046 and 5.672,both P＜0.05).The total effective dose during SPECT/CT imaging were (7.86± 1.98),(7.21±0.81) and (5.71±0.45) mSv (x2 =28.988,P＜ 0.05).There were significant differences between 99Tcm-MAA pulmonary perfusion imaging group and 99Tcm-MDP bone scan group,99Tcm-MIBI parathyroid imaging group(Z=4.967 and 4.994,both P＜0.05).Conclusions The increase in effective dose due to spiral CT during SPECT/CT examination should be concerned.Appropriate utilization and optimization of SPECT/CT is needed.
